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doi:10.1016/j.jfma.2011.06.022Background/Purpose: Men who have sex with men (MSM) are at increased risk for hepatitis A
virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections than the general po-
pulation. Comparisons of the seroprevalence rates of these hepatitis viruses between HIV-
positive and HIV-negative MSM are rarely performed in Taiwan.
Methods: Between January 2009 and June 2010, data on the serologies for HAV, HBV, and HCV
were collected from two groups of patients: HIV-negative MSM, aged 18e40 years, who sought
voluntary counseling and testing (VCT) for HIV infection, and HIV-positive MSM of the same age
group who sought HIV care at the National Taiwan University Hospital. Both groups of patients
were also tested for syphilis.
Results: During the 18-month study period, 690 HIV-negative MSM and 438 HIV-positive MSM
were enrolled and tested for anti-HAV antibody, HBV surface antigen (HBsAg), hepatitis B core
antibody (anti-HBc antibody), and anti-HCV antibody. HIV-positive MSM were older than HIV-
negative MSM (30.5  5.4 vs. 25.8  4.7 years, p < 0.01). For HIV-positive MSM, the mean
CD4 lymphocyte count was 477.6  230.0 cells/mL and 46% of them had undetectable plasma
HIV RNA load (< 40 copies/mL by reverse transcription-polymerase chain reaction assay). The
overall seroprevalence rates of HAV, HBsAg, and HCV in HIV-positive MSM were 15.1%, 16.4%,of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
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432 Y.-T. Tseng et al.and 5.5%, respectively, while in HIV-negative MSM, they were 7.4%, 6.2%, and 0.4%, respec-
tively. In the multivariate analysis, age was significantly associated with seropositivity for
HAV (OR [per one age group increase]: 1.96; 95% CI: 1.6e2.5), HBsAg (OR: 2.02; 95% CI: 1.6
e2.6), anti-HBc (OR: 2.68; 95% CI: 2.3e3.2), anti-HCV (OR: 1.67; 95% CI: 1.0e2.7), and anti-
HBs (OR: 1.25; 95% CI: 1.0e1.5). HIV infection was associated with seropositivity for HBsAg
(OR: 1.73; 95% CI: 1.1e2.7), anti-HBc (OR: 2.44; 95% CI: 1.8e3.3), HCV (OR: 8.91; 95% CI:
2.5e31.4), and syphilis (OR: 11.21; 95% CI: 6.7e18.9).
Conclusion: HIV-positive MSM have a higher seroprevalence rate of HBV and HCV infection than
HIV-negative MSM in Taiwan. Vaccination and safe-sex counseling should be provided to
prevent the transmission of hepatitis viruses among MSM who may be engaged in high-risk
behaviors.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Men who have sex with men (MSM) are at increased risk for
sexually transmitted diseases (STD), such as chlamydia,
gonorrhea, syphilis, hepatitis A virus (HAV) infection,
hepatitis B virus (HBV) infection, hepatitis C virus (HCV)
infection, and human immunodeficiency virus (HIV) infec-
tion, than the general population.1e3 Nevertheless, the risk
for hepatitis virus infections among MSM will vary with
regions of different endemicities of hepatitis virus infec-
tions studied and the extent to which vaccination programs
are implemented for vaccine-preventable hepatitis viruses,
such as HAV and HBV.
Taiwan used to be hyperendemic for HBV infection
before implementation of a nationwide HBV vaccination
program since July 1984.4 For persons born before 1984, the
prevalence of chronic HBV infection was estimated 15e20%
among adults, which declines significantly as well as
hepatocellular carcinoma among those born after 1986 in
serial surveillance studies, regardless of HIV serostatus.5e7
In contrast to HBV, there is no nationwide HAV vaccina-
tion in Taiwan, though HAV vaccination is provided free-of-
charge to aborigines8 and is recommended to those who are
at risk for infection. With improvements in sanitation in
Taiwan, HAV seroprevalence has significantly declined in
younger populations.9,10 Although MSM have a higher HAV
seroprevalence than heterosexuals in Western coun-
tries,11,12 a recent study in Taiwan demonstrated that the
only factor that was associated with anti-HAV seropositivity
was age, and HIV serostatus was not independently asso-
ciated with anti-HAV seropositivity.9
In Taiwan, the prevalence of HCV is estimated at 4e10%
in the general population6,13 and 30e56% in HIV-positive
patients in studies that included different proportions of
injecting drug users (IDUs).14e16 After an outbreak of HIV
infection occurred among IDUs in Taiwan between 2003 and
2007, HCV seropositivity was 95e97% among HIV-positive
IDUs.9,14,17,18 While HCV transmission is significantly more
efficient among IDUs than among MSM, an increasing
number of reports have indicated that HCV infections are
presenting among MSM who may be engaged in risky sexual
contact.19e27
In this study, we aim to compare the seroprevalence
rates of HAV, HBV, and HCV between HIV-positive MSM and
HIV-negative MSM aged between 18e40 years.Patients and methods
Setting and study population
This seroprevalence study was conducted at the National
Taiwan University Hospital, the major referral hospital for
inpatient and outpatient HIV care, which serves as the
largest site for the provision of voluntary counseling and
testing (VCT) for HIV in Taiwan. As a response to the HIV
epidemic in Taiwan, the VCT program was implemented in
1990. In addition to HIV, serologic tests for Treponema
pallidum, HAV (anti-HAV IgG antibody), HBV (hepatitis B
surface antigen [HBsAg], anti-HBs antibody, and hepatitis
B core antibody [IgG anti-HBc antibody]), HCV (anti-HCV
antibody), and Entamoeba histolytica (indirect hemagglu-
tination antibody [IHA]) have also been provided as VCT
services at this hospital since 2006.28 In this study, MSM
aged between 18 and 40 years were enrolled when they
sought VCT for HIV infection between January 2009 and
June 2010. Because few MSM who were also IDUs were
identified, they were excluded from this study. VCT clients
were given a unique code as an identifier that consisted of
his birth year and the initial letter and last four digits of his
identification (ID) card number. The initial letter of the ID
number indicated the birth place of the subjects.
For HIV-positive MSM, serology for the hepatitis viruses,
syphilis, CD4 lymphocyte count, and plasma HIV RNA load
were performed as routine assessments among HIV-infected
MSM when they sought HIV care, and the data was recorded
using a standardized case collection form. A titer of rapid
plasma reagin (RPR)S 4 in this study would be recorded as
syphilis if T pallidum hemagglutination (TPHA) was tested
positive. The study was approved by the research ethics
committee of the hospital and was waived for informed
consent.Laboratory investigations
Determination of anti-HAV antibody status in the serum
samples obtained from HIV-negative MSM were performed
at the VCT site using Hepavase A96 TMB, by following the
instructions of the manufacturer (General Biologicals
Corp., Hsin-Chu, Taiwan), which reported sensitivity of
99.8% and specificity of 99.5%. For HIV-positive MSM, anti-
Table 1 Demographics and seroprevalence of hepatitis
viruses in HIV-positive and -negative MSM aged 18e40 years.
HIV-positive HIV-negative
No. of subjects 438 690
Mean  SD, y 30.5  5.4 25.8  4.7
Age, y
18e22, n (%) 33 (7.5) 198 (28.7)
23e27 101 (23.1) 262 (38.0)
28e33 163 (37.2) 183 (26.5)
34e40 141 (32.2) 47 (6.8)
Positive anti-HAV
antibody, n/N (%)
66/438 (15.1) 51/690 (7.4)
Positive HBsAg, n/N (%) 70/428 (16.4) 43/690 (6.2)
Positive anti-HBc, n/N (%) 221/418 (52.9) 140/690 (20.3)
Positive anti-HCV
antibody, n/N (%)
24/434 (5.5) 3/689 (0.4)
RPR 115/429 (26.8) 32/690 (4.6)
Note: n/N Z number of patients with positive test result/
number of patients with test results.
Abbreviations: HAV, hepatitis A virus; HBsAg, hepatitis B surface
antigen; HCV, hepatitis C virus; RPR, rapid plasma reagin; SD,
standard deviation.
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the hospital with the use of chemiluminescent microparticle
immunoassay (CMIA) (Architect HAVAb-IgG, Abbott Diag-
nostic Division, Germany). Consistency between the two test
kits for detection of the anti-HAV antibody was assessed using
the first 217 blood samples from HIV-negative and HIV-
positive patients, and only two revealed discordant results,
indicating the consistency is higher than 99%.
HBsAg, anti-HBs antibody, and IgG anti-HBc antibody
were determined with the use of enzyme immunoassays
(Abbott Laboratories). Antibodies to HCV were determined
with the use of a third-generation enzyme immunoassay (Ax
SYM HCV III, Abbott Laboratories). Anti-HIV antibodies were
determined using particle agglutination (SFD HIV 1/2 PA;
Bio-Rad FUJIREBIO, Japan) and confirmed using Western
blot (MP Diagnostics HIV BLOT 2.2.; MP Biomedicals Asia
Pacific Pte Ltd, Singapore). Syphilis serology was tested
using RPR card antigen suspension (Macro-Vue RPR Card
Tests; BD, NJ, USA).
Plasma HIV RNA loads were quantified using reverse
transcription-polymerase chain reaction (RT-PCR) assay
(Roche Amplicor, version 1,5; Roche Diagnostics, Branchburg,
NJ, USA) with a lower detection limit of 40 (1.6 log 10) copies/
mL. CD4 counts were determined using FACFlow (BD FACS
Calibur; Becton Dickinson, San Jose, CA, USA).
Statistical analysis
All statistical analyses were performed using SPSS version
17.0 (SPSS, Chicago, IL, USA). Categorical variables were
compared using Fisher’s exact test or the Chi-square test.
Noncategorical variables were compared using the Mann-
Whitney U test. Factors with p value <0.2 were included for
multivariate analysis. Multiple logistic regression analyses
were separately used to determine the factors associated
with seropositivity for HAV, HBV, and HCV. All comparisons
were two-tailed and a p value <0.05 was considered
significant.
Results
During the 18-month study period, 438 HIV-positive MSM
and 690 HIV-negative MSM, who were between 18e40 years
of age, were enrolled. Their characteristics are shown in
Table 1. The mean age of HIV-positive MSM and HIV-
negative MSM were 30.5  5.4 and 25.8  4.7 years,
respectively (p < 0.001); 69.4% of HIV-positive MSM were
>27 years, while only 33.3% of HIV-negative MSM were >27
years (p < 0.001). For HIV-positive MSM, the mean CD4
lymphocyte count was 477.6  230.0 cells/mL, with 88.6%
having a CD4 count >200 cells/mL and 46% an undetectable
plasma HIV RNA load (< 40 copies/mL by RT-PCR) when this
study was conducted (Table 1).
HIV-positive MSM had a significantly higher overall
prevalence of positive anti-HAV antibody (15.1% vs. 7.4%,
p < 0.001), HBsAg (16.4% vs. 6.2%, p < 0.001), anti-HBc
(52.9% vs. 20.3%, p < 0.001), and anti-HCV (5.5% vs. 0.4%,
p < 0.001) than HIV-negative MSM (Table 1). In the subgroup
analysis of persons born after 1986 (age: 18e22 years), we
found that positive anti-HBc antibody was not statistically
significantly associated with HIV infection (6.5% vs. 7.1%,pZ 0.99), while among persons born before 1986, positive
anti-HBc antibody was statistically significantly associated
with HIV infection (56.3% vs. 29.4%, p < 0.001). In the
multivariate analysis, we found that, compared with HIV-
negative MSM, HIV-positive MSM were associated with
a higher risk for seropositivity for HBsAg (odds ratio [OR]:
1.73; 95% CI: 1.1e2.7), anti-HBc (OR: 2.44; 95% CI:
1.8e3.3), HCV (OR: 8.91; 95% CI: 2.5e31.4), and syphilis
(OR: 11.21; 95% CI: 6.7e18.9).
Compared with HIV-positive MSM born before 1986, HIV-
positive MSM born after 1986 had a significantly lower
prevalence of HBsAg (3% vs. 17.5%, p Z 0.03) and anti-HBc
(6.5% vs. 56.3%, p < 0.001). HIV-negative MSM born after
1986 also had a significantly lower prevalence of HBsAg
(1.5% vs. 8.1%, p Z 0.001) and anti-HBc (7.1% vs. 25.61%,
p < 0.001) than HIV-negative MSM born before 1986.
Positive anti-HBs status alone, with negative HBsAg and
negative anti-HBc, among HIV-negative and HIV-positive
MSM was 67.1% (369/550) and 68.6% (131/191), respec-
tively (p Z 0.7). Positive anti-HBs status alone among HIV-
negative and HIV-positive MSM born after 1986 were 52.3%
(103/197) and 55.2% (16/29), respectively (p Z 0.77).
The seroprevalence of each hepatitis virus was associ-
ated with age. The relationship between age and seropos-
itivity for hepatitis virus infections are shown in Fig. 1. The
seropositivity for HAV was increased significantly in patients
>30 years. In the multivariate analysis, we found that,
after adjusted with HIV infection, age was significantly
associated with seropositivity for anti-HAV (OR (per each
age group increment): 1.96; 95% CI: 1.6e2.5), HBsAg (OR:
2.02; 95% CI: 1.6e2.6), anti-HBc (OR: 2.68; 95% CI:
2.3e3.2), anti-HCV (OR, 1.67; 95% CI: 1.0e2.7), and anti-
HBs alone (OR: 1.25; 95% CI: 1.0e1.5) (all p < 0.05).
We also analyzed the distribution of birth places, and
these results are shown in Fig. 2 and Table 2. While we did
not record their past or current residencies after birth,
Figure 1 A. Relationship between age and hepatitis A virus seropositivity. The p values indicate comparisons between HIV-
positive and -negative MSM in the same age group. B. Relationship between age and HBsAg seropositivity. C. Relationship
between age and anti-HBc seropositivity. D. Relationship between age and HCV seropositivity.
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Taipei City) (Table 2). There were no statistically significant
differences in terms of HAV seroprevalence between
patients who were born in Taipei and those who were not
born in Taipei (45/503 vs. 72/625, pZ 0.16) or between the
patients born in northern Taiwan and those born in other
parts of Taiwan (67/701 vs. 50/427, p Z 0.25) (Fig. 2B).Discussion
In this survey conducted among MSM who were aged <40
years in metropolitan Taipei city, we found that HIV-
positive MSM had a higher seroprevalence of HAV, HBV,
and HCV infection than HIV-negative MSM. After adjustment
for HIV serostatus, we found that age was associated with
seropositivity for HBV and HCV infections.
In the published studies conducted in developed coun-
tries,9,12,14,29,30 the seroprevalence of HAV infection is
higher among HIV-positive persons than HIV-negative
persons, and IDUs have the highest seroprevalence rate
for HAV infection. The differences in HAV seroprevalence
between different studies from developed countries may
be related to the age and risk group for HIV transmission of
the study populations and endemicity of HAV infection at
the study sites because IDU and older age are associated
with a significantly higher HAV seroprevalence.9 In this
study, the HAV seroprevalence among MSM aged < 40 yearsis 10.4%, which is similar to a survey among military recruits
with similar gender and age groups in the United states in
2007,31 but is higher than that among the general pop-
ulation in Finland32 and lower than other Asian countries,
such as Korea, where similar trends of HAV seroprevalence
are also noted.33 Compared with the HAV seroprevalence
rates in different age groups of MSM reported in our
previous study,9 we found that HAV seroprevalence
decreased further in this study. We also found that
HIV-positive MSM have a higher HAV seroprevalence than
HIV-negative MSM (15.1% vs. 7.4%, p < 0.01); however, we
were not able to find a statistically significant association
between HAV and HIV infection in the multivariate analysis.
Consistent with the findings of our previous study,9 which
demonstrated that HAV seroprevalence increased with age,
this study shows a rapid increase of HAV seropositivity
between 28e33 years and 34e40 years (Fig. 1A).
Confounding factors of HAV seropositivity may include
birth place and places of early residency. According to one
recently published study by Su et al, the birth period and
childhood residence areas were significantly associated
with HAV seropositivity in Taiwan.34 In this study, more than
50% of the subjects were born in Taipei (Taipei City and
New Taipei City) (Table 2 and Fig. 2). While information on
the early and current residencies of the subjects was not
collected, there were no statistically significant differences
in terms of HAV seropositivity between subjects who were
born in Taipei and those who were born in other places; or
Figure 2 A. Distribution of birth places among HIV-positive and -negative subjects. B. HAV seroprevalence among HIV-positive
and -negative subjects with different places of birth. No statistically significant differences were observed between patients
born in Taipei (p Z 0.16), non-Taipei regions, those born in northern Taiwan, and those born in other parts of Taiwan (p Z 0.25).
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those who were born in other parts of Taiwan (Fig. 2B).
These findings should be informative for public health
experts to make recommendations for the appropriate
timing of HAV vaccinations in this high-risk population.
In Western countries, HBV transmission mainly occurs
when persons are engaged in risky behaviors for HIV and
HBV transmissions and, therefore, HIV-positive persons
have a higher prevalence of HBV infection than the general
population.35 In Taiwan, where chronic HBV infection used
to be hyperendemic before the implementation of
a nationwide HBV vaccination program in 1984, the sero-
prevalence of HBsAg in HIV-positive persons (20.3%) is
similar to that of the general population of the same age
group17 because most HBV infections are contracted in the
perinatal period and childhood.36,37 However, the findings
of significantly higher seroprevalence rates of anti-HBc in
HIV-positive MSM than HIV-negative MSM in this study, and
in IDUs than in other risk groups of the same age groups bySun et al, suggest that subsequent risky behaviors of HIV
transmission still increase the risk of HBV transmission
among persons who did not receive HBV vaccination or who
did not have sufficient protective antibodies for HBV despite
vaccination.15 In the study by Sheng et al,38 the incidence of
HBV infection among HIV-infected persons who were sero-
negative to all HBV markers was estimated at 9.69 per 100
person-years of follow-up, which argues strongly for HBV
vaccination in MSM who are nonimmune to HBV infection.
This study demonstrates the effectiveness of HBV vacci-
nation in both HIV-positive and -negative MSM. Compared
with HIV-positive MSM born before 1986, HIV-positive MSM
born after 1986 have a significantly lower prevalence of
HBsAg (3% vs. 17.5%) and anti-HBc (6.5% vs. 56.3%). Like-
wise, HIV-negative MSM born after 1986 have a significantly
lower prevalence of HBsAg (1.5% vs. 8.1%) and anti-HBc
(7.1% vs. 25.6%) than HIV-negative MSM born before 1986.
The HBV seroprevalence in MSM of the youngest age group is
similar to that reported by Lu et al in persons of high-school
Table 2 Distribution of birth place and seroprevalence of
HAV among HIV-positive and -negative MSM.
Anti-HAV-
positive
Anti-HAV-
negative
P
Taipeia HIV-positive 23 160
HIV-negative 22 298
Total 45 458
Non-Taipei HIV-positive 43 212
HIV-negative 29 341
Total 72 553 0.16
Northern Taiwanb HIV-positive 34 229
HIV-negative 33 405
Total 67 634
Central, southern,
and eastern
Taiwanc
HIV-positive 32 143
HIV-negative 18 234
Total 50 377 0.25
a Taipei City and New Taipei City.
b North Taiwan: Taipei City, New Taipei City, Keelung, I-Lan,
Taoyuan, Miao-Li, Hsin-Chu City and County, Yang-Ming Mountain.
c Taichung City, Tainan City, Kaohsiung City, Nan-Tou, Chang-
Hwa, Yun-Lin County, Ping-Tung, Hualien, Tai-Tung, and Off-
Shore islands.
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Besides, according to the report by Ni et al, the seropreva-
lence rate of HBsAg among persons aged 15e20 years was
7% in 1999, and anti-HBc, which represents HBV infection,
was 20.6% of persons aged 15e20 years in 1999.40
In this study, we did not obtain data on the seropreva-
lence of hepatitis viruses in the general population for
comparison purposes. In our previous study, the seropre-
valence of HBsAg and anti-HBc was compared between
HIV-positive and HIV-negative persons born before 1984.17
Compared with HIV-negative persons born before July
1984, HIV-positive persons born before July 1984 had
a significantly higher seroprevalence of HBsAg (20.3% vs.
15.5%, p < 0.001) and anti-HBc (78.9% vs. 72.1%,
p < 0.001).17 In addition, a significant decline in HBV
seroprevalence among both HIV-negative and -positive
persons born in the era of the nationwide HBV vaccination
in Taiwan has also been shown.17 In this study, positive anti-
HBs status alone, which indicates the prevalence of HBV
vaccination-related protection, among HIV-negative and
-positive MSM were 67.1% and 68.6%, respectively. Both
rates are higher than that reported by Lu et al for persons
of high-school or college age born after 1986 and received
HBV vaccination at birth.39 In HIV-positive patients, the
anti-HBs antibody titer may decline with age and immu-
nodeficiency.41 The higher prevalence of anti-HBs positivity
among MSM may be related to natural boosters acquired
through high-risk sexual contact, although more behavioral
studies are needed to confirm this hypothesis.
Sharing contaminated needles and solvent is an efficient
route for HCV transmission, which lends explanations to
the extremely high HCV seroprevalence among IDUs who
acquired HIV infection in Taiwan between 2003e2007.18,42
With the implementation of a harm-reduction program by
providing clean needles and methadone to IDUs, HIV
infections among IDUs significantly declined. In recent
years, outbreaks of sexually transmitted, acute, or recentHCV infections have raised concern in several European
countries.19e24,43 In the Netherlands, where the prevalence
of HCV in HIV-infected MSM has been on the rise since
the mid-1990s,25 sexual practices that lead to rectal
bleeding and the use of snorting drugs were identified as
risk factors for acute HCV infection.26 In this study, we
found that HCV seroprevalence was significantly higher in
HIV-positive MSM than HIV-negative MSM (5.5% vs. 0.4%)
(Fig. 1D) and HIV infection and age were statistically
significantly associated with HCV seropositivity. In a recent
investigation, we also found an increased incidence of
recent HCV infections among non-IDU, HIV-infected
patients between 1994e2010, and recently syphilis was
identified as an independent risk factor for HCV infection.27
These findings should alert healthcare providers to the
continued risk of the transmission of HCV among MSM, and
safe-sex counseling should be consistently provided.
There are several limitations to this study. First, the
persons who seek VCT services at our hospital and HIV-
infected persons seeking HIV care at our outpatient clinics
may not be representative of the whole MSM population in
Taiwan, although the annual number of VCT provided by
this hospital accounts for one-fourth of the total number of
VCT provided at the designated hospitals for HIV care
around Taiwan. Second, the cross-sectional study design
precludes us from estimating the incidences of HAV, HBV,
and HCV infection among MSM. Third, we did not collect
data on socioeconomic status or history of HAV and HBV
vaccinations, although offering HAV vaccination was not
a common practice in Taiwan and the HBV vaccine coverage
rate is higher than 98% among persons < 22 years.39,40
Fourth, although we found that age was an independent
risk factor of seropositivity for anti-HAV, HBsAg, anti-HCV,
and amount of risky exposure may limit interpretation of
our findings. Fifth, we did not further examine the sero-
prevalence of hepatitis D virus (HDV) among HBsAg-positive
MSM in this age range, although our recent study revealed
that HDV seroprevalence among HIV-infected non-IDUs and
HIV-uninfected non-IDUs who were also HBsAg-positive was
9.3% and 2.3%, respectively.44
We conclude that HIV-positive MSM have a higher sero-
prevalence of HBV and HCV infection than HIV-negative
MSM in Taiwan. Vaccination and safe-sex counseling should
be provided to prevent the transmission of hepatitis viruses
among MSM who may be engaged in high-risk behaviors.References
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